Improved Atrial Differentiation of Human Pluripotent Stem Cells by Activation of Retinoic Acid Receptor Alpha (RARα).

atrial cardiomyocyte differentiation hPSC-derived AM retinoic acid signaling

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
13 Apr 2022
Historique:
received: 03 02 2022
revised: 24 03 2022
accepted: 10 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

Human pluripotent stem cell (hPSC)-derived cardiomyocytes have proven valuable for modeling disease and as a drug screening platform. Here, we depict an optimized protocol for the directed differentiation of hPSCs toward cardiomyocytes with an atrial identity by modulating the retinoic acid signaling cascade in spin embryoid bodies. The crucial steps of the protocol, including hPSC maintenance, embryoid body (EB) differentiation, the induction of cardiac mesoderm, direction toward the atrial phenotype, as well as molecular and functional characterization of the cardiomyocytes, are described. Atrial cardiomyocytes (AMs) can be generated within 14 days. Most importantly, we show that induction of the specific retinoic acid receptor alpha (RARα) increased the efficiency of atrial differentiation to 72% compared with 45% after modulating the retinoic acid (RA) pathway with all-trans RA (atRA). In contrast, the induction of RARβ signaling only had a minor impact on the efficiency of atrial differentiation (from about 45% to 50%). Similarly, the total yield of AM per EB of 5000 hPSCs was increased from 10,350 (2.07 per hPSC) to 16,120 (3.22 per hPSC) while selectively modulating RARα signaling. For further purification of the AMs, we describe a metabolic selection procedure that enhanced the AM percentage to more than 90% without compromising the AM yield (15,542 per EB, equal to 3.11 per hPSC) or functionality of the AMs as evaluated by RNAseq, immunostaining, and optical action potential measurement. Cardiomyocytes with distinct atrial and ventricular properties can be applied for selective pharmacology, such as the development of novel atrial-specific anti-arrhythmic agents, and disease modeling, including atrial fibrillation, which is the most common heart rhythm disorder. Moreover, fully characterized and defined cardiac subtype populations are of the utmost importance for potential cell-based therapeutic approaches.

Identifiants

pubmed: 35455744
pii: jpm12040628
doi: 10.3390/jpm12040628
pmc: PMC9032956
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : TOP-ZonMw grant
ID : TOP-00812-98-17061
Organisme : TKI
ID : LSHM20063
Organisme : Hartstichting
ID : 2019T104

Références

Front Physiol. 2019 Jun 27;10:818
pubmed: 31316396
Cell Res. 2011 Apr;21(4):579-87
pubmed: 21102549
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biomed Eng. 2022 Apr;6(4):389-402
pubmed: 34992271
Cell Mol Life Sci. 2017 Oct;74(20):3711-3739
pubmed: 28573431
Cell Stem Cell. 2017 Aug 3;21(2):179-194.e4
pubmed: 28777944
Stem Cells Transl Med. 2014 Dec;3(12):1473-83
pubmed: 25355733
Stem Cell Reports. 2015 Jun 9;4(6):1112-24
pubmed: 26028532
Circ Cardiovasc Genet. 2011 Apr;4(2):123-33
pubmed: 21282332
Stem Cell Reports. 2017 Dec 12;9(6):1765-1779
pubmed: 29173897
Nat Commun. 2020 Jan 7;11(1):75
pubmed: 31911598
Cell Stem Cell. 2013 Jan 3;12(1):127-37
pubmed: 23168164
Differentiation. 2008 Nov;76(9):971-80
pubmed: 18565102
Cell Rep. 2015 Oct 27;13(4):733-745
pubmed: 26489474
Nat Protoc. 2008;3(5):768-76
pubmed: 18451785
Stem Cell Res. 2010 Mar;4(2):107-16
pubmed: 20034863
EMBO Mol Med. 2015 Feb 19;7(4):394-410
pubmed: 25700171
Lancet. 2010 Apr 3;375(9721):1212-23
pubmed: 20334907
Sci Rep. 2017 Jul 13;7(1):5268
pubmed: 28706272
Exp Cell Res. 2014 Oct 1;327(2):297-306
pubmed: 24836851
Development. 2003 Nov;130(22):5363-74
pubmed: 13129847
Stem Cell Res. 2017 Mar;19:94-103
pubmed: 28110125
Stem Cell Reports. 2018 Dec 11;11(6):1378-1390
pubmed: 30416051
PLoS One. 2015 May 13;10(5):e0126596
pubmed: 25970162
Circulation. 2014 Feb 25;129(8):837-47
pubmed: 24345399
PLoS One. 2014 Jul 10;9(7):e101316
pubmed: 25010565
Development. 2002 Aug;129(15):3563-74
pubmed: 12117807

Auteurs

Verena Schwach (V)

Department of Applied Stem Cell Technologies, TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.

Carla Cofiño-Fabres (C)

Department of Applied Stem Cell Technologies, TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.

Simone A Ten Den (SA)

Department of Applied Stem Cell Technologies, TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.

Robert Passier (R)

Department of Applied Stem Cell Technologies, TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.
Department of Anatomy and Embryology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Classifications MeSH